In NSCLC patients, bsPD-L1 levels were almost unchanged during ICI treatment (Figures 1C, D), whereas anti-PD-L1, but not anti-PD-1, treatment increased sPD-L1 levels (Figure 1E). The gene discussed is SPDL1; the disease is non-small cell lung carcinoma.